You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment.
Federal mandates requiring frequent SARS-CoV-2 testing for nursing home employees and significant purchases of rapid antigen tests from HHS have raised concerns about capacity.
The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.
The Medicare Administrative Contractor will cover ctDNA tests if the patient has a personal history of colorectal cancer.
Under a proposed rule, devices given FDA's breakthrough designation would, upon receiving FDA market authorization, immediately be covered by Medicare.
The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.
The report noted that savings from the lower payment rates were offset by increased spending on other tests, including genetic tests.
Issued this week, the proposed fee schedule would cut overall pathology service payments by 9 percent compared to 2020 and independent lab services by 5 percent.
In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.
The new funding is being provided to nursing homes to address needs in the wake of the coronavirus pandemic, including increased SARS-CoV-2 testing.